Moreover, IL-37 treatment conferred a cancer-specific immunity to previously susceptible mice upon treatment with rIL-37 such that they failed to succumb to a re-challenge despite increases in inoculum size of active malignant cells [96]. This evidence concerns the gene IL37 and cancer.